candesartan has been researched along with Leukemia, Monocytic, Acute in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Leukemia, Monocytic, Acute: An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yanagitani, Y | 1 |
| Rakugi, H | 1 |
| Okamura, A | 1 |
| Moriguchi, K | 1 |
| Takiuchi, S | 1 |
| Ohishi, M | 1 |
| Suzuki, K | 1 |
| Higaki, J | 1 |
| Ogihara, T | 1 |
1 other study available for candesartan and Leukemia, Monocytic, Acute
| Article | Year |
|---|---|
Angiotensin II type 1 receptor-mediated peroxide production in human macrophages.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cell Different | 1999 |